Key facts
- It has raised $5.8M; the latest was Accelerator/Incubator in Apr 2025.
- Notable investors include Plug and Play Tech Center, SOSV, Harvard Innovation Launch Lab, HAX, Launch Africa Ventures — 24 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 24 names
- ·Watchlist + deal alerts for RxAll
- ·The full record, as it builds
Funding rounds
No funding rounds for RxAll are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About RxAll
Developer of a deep learning hyperspectral IoT platform designed for authenticating drugs in real-time. The company's platform works through spectrometers and a cloud data set of spectral signatures of medicines to carry out non-destructive product authentication, enabling pharma manufacturers to get information in real-time about counterfeiting of their products and making high-quality medicines accessible to everyone at affordable prices.
- Sector
- Healthcare
- HQ
- New Haven, CT, United States
- Founded
- 2016
- Employees
- 24
- Website
- rxall.net/
- Ownership
- Privately Held (backing)
RxAll doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RxAll shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RxAll in its N-PORT filings yet. We sweep new filings monthly.